CV Risk Reduction in Patients with DM and CVD- July 27, 2020

Event Information

Share this event

Date and Time



Online Event

Event description
CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD - July 27, 2020

About this Event

CHEP+ Clinical Practice Guidelines Program

CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD)

July 27, 2020 • 7-9 PM Eastern Time

Presented by: Dr. Richard Choi, MD, FRCPC

Moderated by: Dr. Sheldon Tobe, MD, FRCPC, MScCH (HPTE), FACP, FAHA

Dr. Choi is Staff Cardiologist at Unity Health Toronto

Dr. Tobe is a specialist in Hypertension and Nephrology, Division of Nephrology, Sunnybrook Health Sciences Centre, and is the University of Toronto PostgraduateFellowship Director – Nephrology. He is a Professor in the Faculty of Medicine, University of Toronto and Northern Ontario School of Medicine


  1. Describe the patient who should be treated with an SGLT2i or GLP-1 RA
  2. Explain the rational for this treatment and the potential benefits
  3. Describe the steps for initiating and monitoring therapy for patients with diabetes

Accreditation: This Group Learning program has been certified by the Canadian College of Family Physicians for up to 6 Mainpro+ credits for the 2-hour presentation (including a practice reflection exercise to be completed 3 months after the session).

This session takes place online through Microsoft Teams. Before the session you will receive an email asking you to register an account for Microsoft Teams and download the app onto your computer, tablet or mobile phone. You will receive an email before the session with the details to join the workshop online.


How can I contact the organizer with any questions? To contact the organizer, email: Diane Hua at / (416) 710-3892.

To learn more: Please visit the event website:

Share with friends

Date and Time


Online Event

Save This Event

Event Saved